AzTrials
AzTrials

Acute AbdomenNCT05295251

The Commonest Medical, Surgical, and Oncological Causes of Acute Abdomen in Adults With COVID-19. A Prospective Observational Study.

An observational study of Acute Abdomen, run by Zagazig University at 1 site in Egypt.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Coronaviruses are a large family of viruses that can cause mild to severe respiratory infections. 2019-nCoV is a novel coronavirus that was discovered in Wuhan, China. Since its discovery in humans in late 2019, it has had a global, rapid spread. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Acute Abdomen
What is being tested?
medical ,oncological and surgical treatment of cases of acute abdomen
How many people
910 participants
Where
1 siteEgypt
Study dates
1 May 2020to 28 Feb 2022
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adult patients > 18 years of age, both sexes, admitted to the emergency department or already admitted but complaining of an acute abdomen, and diagnosed with COVID-19 using a thoracic computed tomography (CT) scan and/or reverse transcription polymerase chain reaction (RT-PCR) of SARS-CoV-2 RNA, as per the Institute Pasteur protocol and WHO technical guidelines [8]. Patients younger than 18 years of age and those who were not confirmed to be COVID-19 positive were excluded from the study. All patients who underwent chest computed tomography (CT) and a comprehensive panel of routine laboratory tests, which included a complete blood count, urinalysis, blood biochemistry, and blood coagulation function.

Who may be able to join

  • >18 years
  • male and female
  • covid-19 positive
  • acute abdomen

Who cannot join

  • < 18 years
  • unsure diagnosis of covid-19

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Tamer Alnaimy

    Zagazig, Sharqia Province, 1234

Other trials in Egypt

About this study

Coronaviruses are a large family of viruses that can cause mild to severe respiratory infections. 2019-nCoV is a novel coronavirus that was discovered in Wuhan, China. Since its discovery in humans in late 2019, it has had a global, rapid spread. Dry cough, fever, and fatigue are the most common symptoms in the first two to 14 days after exposure.

At the moment, it is unknown how common gastrointestinal symptoms are. However, COVID-19's initial clinical presentations have become more evident as the pandemic has progressed and case data has been gathered, and literature suggests that digestive symptoms are prevalent .

Read more

In a recent systematic review and meta-analysis of 47 studies involving 10,890 patients with COVID-19, the pooled prevalence of gastrointestinal symptoms were 7.7 % for diarrhea, 7.8% for nausea/vomiting, and 2.7% for abdominal pain. Only a few cases of isolated abdominal pain have been reported.

A wide range of diseases can cause acute abdominal pain, and diagnosing them can be difficult. The examining physician should prioritize life-threatening conditions that may necessitate immediate surgical intervention with such a broad differential diagnosis to avoid further mortality or morbidity. The objective of this study was to determine the characteristics, incidence, severity and of acute abdominal pain (medical and surgical causes) during the COVID-19 pandemic.

Read the detailed description

Coronaviruses are a large family of viruses that can cause mild to severe respiratory infections. 2019-nCoV is a novel coronavirus that was discovered in Wuhan, China. Since its discovery in humans in late 2019, it has had a global, rapid spread. Dry cough, fever, and fatigue are the most common symptoms in the first two to 14 days after exposure.

At the moment, it is unknown how common gastrointestinal symptoms are. However, COVID-19's initial clinical presentations have become more evident as the pandemic has progressed and case data has been gathered, and literature suggests that digestive symptoms are prevalent .

In a recent systematic review and meta-analysis of 47 studies involving 10,890 patients with COVID-19, the pooled prevalence of gastrointestinal symptoms were 7.7 % for diarrhea, 7.8% for nausea/vomiting, and 2.7% for abdominal pain. Only a few cases of isolated abdominal pain have been reported.

A wide range of diseases can cause acute abdominal pain, and diagnosing them can be difficult. The examining physician should prioritize life-threatening conditions that may necessitate immediate surgical intervention with such a broad differential diagnosis to avoid further mortality or morbidity. The objective of this study was to determine the characteristics, incidence, severity and of acute abdominal pain (medical and surgical causes) during the COVID-19 pandemic.

Acute abdominal pain in COVID-19 patients poses a diagnostic quandary for clinicians. Delays in treating an acute abdomen can lead to severe complications and even death. In contrast, performing unnecessary surgery on COVID-19 patients results in increased morbidity and mortality, increased strain on healthcare resources, and an increased risk of exposure for healthcare workers in operative fields. This study aimed to determine the characteristics, incidence and severity, and of various medical and surgical causes of acute abdomen in COVID-19. According to our study, gastritis is the most common medical cause of acute abdomen (19.2%). While acute appendicitis (42.4%), acute cholecystitis (11%), and biliary colic (9.8%) are the most frequently encountered surgical causes of acute abdomen, acute pancreatitis occurred in (3%) of cases and mainly was benign in course. Except for acute appendicitis, intestinal ischemia and liver abscesses, the severity of all causes of acute abdomen did not worsen.

Abdominal pain is a less frequent symptom of COVID-19 infection than anorexia, nausea/vomiting, or diarrhea. Abdominal pain is prevalent in 3.9-6.8% of the population .

Conditions
Acute Abdomen
Being tested
medical ,oncological and surgical treatment of cases of acute abdomen
Medical subject headings
Abdomen, Acute

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • medical ,oncological and surgical treatment of cases of acute abdomenOther

    medical treatment and surgical intervention during covid-19 pandemic

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. characteristic, severity and incidence of acute abdomen

    incidence in %

    Measured: 2 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Mar 2022
  2. Study start1 May 2020
  3. Primary completion28 Feb 2022
  4. Study completion28 Feb 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
910 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05295251
Sponsor's protocol ID
acute abdomen in covid
Status last verified
Sep 2022
First submitted
24 Mar 2022
Last updated
7 Sep 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Acute Abdomen, run by Zagazig University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 7 Sep 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

characteristic, severity and incidence of acute abdomen (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 Sep 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in